Difference between revisions of "Adrian Thomas"
(salesman and Event 201 participant) |
(tidy) |
||
| Line 2: | Line 2: | ||
|wikipedia= | |wikipedia= | ||
|Linkedin=https://www.linkedin.com/in/adrianthomasmd | |Linkedin=https://www.linkedin.com/in/adrianthomasmd | ||
| − | |constitutes=pharmaceutical executive | + | |constitutes=pharmaceutical executive,Big Pharma/lobbyist |
|image=Adrian thomas.jpg | |image=Adrian thomas.jpg | ||
| − | |interests=vaccines, pandemics, lobbyism | + | |interests=vaccines, pandemics, lobbyism |
|nationality=Australian? | |nationality=Australian? | ||
|birth_date= | |birth_date= | ||
| Line 12: | Line 12: | ||
|parents= | |parents= | ||
|alma_mater=University of Melbourne, Monash University | |alma_mater=University of Melbourne, Monash University | ||
| − | |description=Pharma executive | + | |description=Pharma executive who attended [[Event 201]] Covid dry-run. |
| + | |employment={{job | ||
| + | |title=Vice President Global Strategy Programs & Policy for Global Public Health | ||
| + | |start=Jan 2016 | ||
| + | |end= | ||
| + | |employer=Johnson & Johnson | ||
| + | |description=Attended [[Event 201]] Covid dry-run | ||
| + | }} | ||
}} | }} | ||
| − | '''Adrian Thomas''' is a senior executive at [[big pharma]] company [[Johnson & Johnson]] (J&J), where he is responsible for making sure J&J gets (lucrative) market access in global public health programs. He participated in the notorious 2019 [[Event 201]] pandemic exercise<ref>https://www.centerforhealthsecurity.org/event201/players/thomas.html</ref>. | + | '''Adrian Thomas''' is a senior executive at [[big pharma]] company [[Johnson & Johnson]] (J&J), where he is responsible for making sure J&J gets (lucrative) market access in global public health programs. He participated in the notorious 2019 [[Event 201]] pandemic exercise<ref name=event>https://www.centerforhealthsecurity.org/event201/players/thomas.html</ref>. |
| − | == | + | ==Background== |
| − | + | Adrian Thomas is a Fellow of the Royal Australasian College of Physicians and the College of Medial Administrators. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the [[University of Melbourne]] in Australia, and was a NHMRC research scholar at the Department of Epidemiology & Preventive Medicine at [[Monash University]].<ref>https://www.linkedin.com/in/adrianthomasmd</ref> | |
| − | Adrian Thomas is a Fellow of the Royal Australasian College of Physicians and the College of Medial Administrators. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the [[University of Melbourne]] in Australia, and was a NHMRC research scholar at the | ||
| − | Prior to joining J&J, | + | ==Career== |
| + | Prior to joining [[J&J]], Thomas worked for pharma companies [[Schering-Plough]] and [[Eli Lilly]], with medical affairs, drug development and product management.<ref name=event/> | ||
| − | Adrian Thomas | + | Since 2016, Adrian Thomas has worked as Vice President for Global Public Health at [[Johnson & Johnson]]. He is responsible for global [[public health]] programs and strategy addressing Global Health Security threats and [[pandemic]] preparedness including antimicrobial resistance (AMR), Multi Drug Resistant Tuberculosis (MDRTB), [[Ebola]], [[Dengue Fever]], [[HIV vaccines]] amongst others. His lobbyist areas include area strategy, public health, market access, and pharmaceutical policy. He has held numerous roles in lobbyist ventures such as market access and product management, including Global Head of Market Access for [[Janssen Pharmaceutica|Janssen]] (owned by J&J) & Global Head of Access for Medical Devices, for Johnson & Johnson, as well as roles in risk management and drug safety, including Global Head of Benefit Risk Management and Chief Safety Officer for Janssen.<ref name=event/> |
| − | He is a Board Member in the [[AMR Industry Alliance]], an business alliance of pharmaceutical companies working to meet market needs | + | He is a Board Member in the [[AMR Industry Alliance]], an business alliance of [[pharmaceutical companies]] working to meet market needs for new classes of antibiotics and breakthrough mechanisms, collaborating with other [[stakeholders]] tod encourage the uptake of [[vaccines]] and diagnostics tools.<ref>https://www.amrindustryalliance.org/why-amr/</ref> |
He is a Fellow at [[The Aspen Institute]]. | He is a Fellow at [[The Aspen Institute]]. | ||
Latest revision as of 02:14, 14 July 2023
 Adrian Thomas  (pharmaceutical executive, Big Pharma/lobbyist) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | ||||||||||||||
| Nationality | Australian? | |||||||||||||
| Alma mater | University of Melbourne, Monash University | |||||||||||||
| Interests | • vaccines • pandemics • lobbyism | |||||||||||||
Pharma executive who attended Event 201 Covid dry-run.
| ||||||||||||||
Adrian Thomas is a senior executive at big pharma company Johnson & Johnson (J&J), where he is responsible for making sure J&J gets (lucrative) market access in global public health programs. He participated in the notorious 2019 Event 201 pandemic exercise[1].
Background
Adrian Thomas is a Fellow of the Royal Australasian College of Physicians and the College of Medial Administrators. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Melbourne in Australia, and was a NHMRC research scholar at the Department of Epidemiology & Preventive Medicine at Monash University.[2]
Career
Prior to joining J&J, Thomas worked for pharma companies Schering-Plough and Eli Lilly, with medical affairs, drug development and product management.[1]
Since 2016, Adrian Thomas has worked as Vice President for Global Public Health at Johnson & Johnson. He is responsible for global public health programs and strategy addressing Global Health Security threats and pandemic preparedness including antimicrobial resistance (AMR), Multi Drug Resistant Tuberculosis (MDRTB), Ebola, Dengue Fever, HIV vaccines amongst others. His lobbyist areas include area strategy, public health, market access, and pharmaceutical policy. He has held numerous roles in lobbyist ventures such as market access and product management, including Global Head of Market Access for Janssen (owned by J&J) & Global Head of Access for Medical Devices, for Johnson & Johnson, as well as roles in risk management and drug safety, including Global Head of Benefit Risk Management and Chief Safety Officer for Janssen.[1]
He is a Board Member in the AMR Industry Alliance, an business alliance of pharmaceutical companies working to meet market needs for new classes of antibiotics and breakthrough mechanisms, collaborating with other stakeholders tod encourage the uptake of vaccines and diagnostics tools.[3]
He is a Fellow at The Aspen Institute.
Events Participated in
| Event | Start | End | Location(s) | Description |
|---|---|---|---|---|
| Event 201 | 18 October 2019 | 18 October 2019 | New York US | A Johns Hopkins Center for Health Security/World Economic Forum/Bill & Melinda Gates Foundation sponsored large scale simulation of a global coronavirus pandemic predicting an apocalyptic outcome. Held October 2019. |
| Preventing Global Catastrophic Biological Risks | 14 February 2020 | 16 February 2020 | Germany Munich Security Conference Munich | Simulation of a global influenza pandemic predicting an apocalyptic outcome. Held February 2020, with a who-is-who of pandemic planners. Held February 2020. |
